WO1992020352A1 - Substance destinee au traitement des maladies causees par des micro-organismes et procede d'elaboration et d'utilisation d'une telle substance - Google Patents
Substance destinee au traitement des maladies causees par des micro-organismes et procede d'elaboration et d'utilisation d'une telle substance Download PDFInfo
- Publication number
- WO1992020352A1 WO1992020352A1 PCT/BG1991/000001 BG9100001W WO9220352A1 WO 1992020352 A1 WO1992020352 A1 WO 1992020352A1 BG 9100001 W BG9100001 W BG 9100001W WO 9220352 A1 WO9220352 A1 WO 9220352A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- sodium thiosulphate
- microorganisms
- diseases caused
- acid
- Prior art date
Links
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 title claims abstract description 33
- 239000002253 acid Substances 0.000 title claims abstract description 32
- 239000004133 Sodium thiosulphate Substances 0.000 title claims abstract description 29
- 235000019345 sodium thiosulphate Nutrition 0.000 title claims abstract description 29
- 238000011282 treatment Methods 0.000 title claims abstract description 28
- 201000010099 disease Diseases 0.000 title claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 18
- 244000005700 microbiome Species 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000007864 aqueous solution Substances 0.000 claims abstract description 15
- 150000007513 acids Chemical class 0.000 claims abstract description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005864 Sulphur Substances 0.000 claims abstract description 8
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims abstract description 7
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 6
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000003780 insertion Methods 0.000 abstract description 2
- 230000037431 insertion Effects 0.000 abstract description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- -1 chemical compounds sodium thiosulphate Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
Definitions
- antibiotics At present for treatment of these diseases are used antibiotics, sulphamides, organic compounds of arsenic, bismuth etc; They all exert a positive impact for favourable running of the healing process but their efficiency is some times unsufficient and to some extent they may have a harmful effect.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Substance destinée au traitement des maladies causées par des micro-organismes, constituée d'un mélange de solutions aqueuses, de thiosulphate de sodium et d'acides faibles, en particulier d'acides ascorbique. Le procédé d'élaboration et d'utilisation de cette substance consiste à mélanger ses composants en conditions stériles à température ambiante. Pour l'administration intraveineuse, la substance est de préférence conditionnée en seringue par aspiration consécutive des composants dans une capsule adaptée à l'administration locale. La substance est constituée d'un mélange de deux composants. Sont introduits dans l'organisme, outre l'excédent de thiosulphate de sodium n'ayant pas subit de réaction et le mélange de sels de sodium, d'acide, de soufre et de NaHSO3. Cette préparation, et son administration dans l'organisme, constitue un moyen rationnel et original d'administration de telles substances, garantissant une interaction compléte avec les processus du métabolisme, de manière à obtenir un effet thérapeutique énergique. Les essais réalisés font apparaître que cette substance exerce un vaste éventail d'effets contre les micro-organismes pathogènes, tout en étant pratiquement sans danger.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG9440891 | 1991-05-13 | ||
| BG94408 | 1991-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1992020352A1 true WO1992020352A1 (fr) | 1992-11-26 |
Family
ID=3923733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BG1991/000001 WO1992020352A1 (fr) | 1991-05-13 | 1991-06-19 | Substance destinee au traitement des maladies causees par des micro-organismes et procede d'elaboration et d'utilisation d'une telle substance |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU8051891A (fr) |
| WO (1) | WO1992020352A1 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579854B1 (en) * | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
| US6664239B2 (en) | 1997-05-06 | 2003-12-16 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
| US6756369B2 (en) | 1997-05-06 | 2004-06-29 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
| US6884784B1 (en) | 1997-05-06 | 2005-04-26 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2445679A1 (de) * | 1973-09-25 | 1975-03-27 | Merieux Inst | Neue immunitaets-stimulierende medikamente |
| US4474759A (en) * | 1982-07-22 | 1984-10-02 | Vojislav Petrovich | Method of treating bacterial, viral or parasitic diseases |
| US4929378A (en) * | 1986-07-03 | 1990-05-29 | Takeda Chemical Industries, Ltd. | Bath preparation |
-
1991
- 1991-06-19 WO PCT/BG1991/000001 patent/WO1992020352A1/fr active Application Filing
- 1991-06-19 AU AU80518/91A patent/AU8051891A/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2445679A1 (de) * | 1973-09-25 | 1975-03-27 | Merieux Inst | Neue immunitaets-stimulierende medikamente |
| US4474759A (en) * | 1982-07-22 | 1984-10-02 | Vojislav Petrovich | Method of treating bacterial, viral or parasitic diseases |
| US4929378A (en) * | 1986-07-03 | 1990-05-29 | Takeda Chemical Industries, Ltd. | Bath preparation |
Non-Patent Citations (4)
| Title |
|---|
| Dialog Information Services, File 351, World Patent Index 81-91, Dialog accession no. 007066043, Ishimoto T: "Antimycotic agent without irritant effect or strong smell contg. thiophosphate,alum and acid", DE 3629385, A, 870305, 8710 (Basic) * |
| Dialog Information Services, File 351, World Patent Index 81-91, Dialog accession no. 007315007, Kaza Vaskhnil veter: "Salt solution veterinary treat calf; contain supplementary salt ascorbic acid increase therapeutic efficiency", SU 1246448, A, 870223, 8744 (Basic) * |
| National Library of Medicin, database Medline, accession no. 89294359, Margulis FB et al: "Use of sodium thiosulfate with fibrinolysin and endolypmphatic antibacterial therapy in the com- plex treatment of suppurative wounds", Klin Khir 1989;(1):56 * |
| National Library of Medicin, database Medline, accession no. 91239479, Starostenko EV et al: "The use of antioxidants in the complex therapy of patients with infiltrating pulmonary tuberculosis", Probl Tuberk 1991; (1): 9-11 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579854B1 (en) * | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
| US6664239B2 (en) | 1997-05-06 | 2003-12-16 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
| US6756369B2 (en) | 1997-05-06 | 2004-06-29 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
| US6884784B1 (en) | 1997-05-06 | 2005-04-26 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
Also Published As
| Publication number | Publication date |
|---|---|
| AU8051891A (en) | 1992-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69327642T2 (de) | Verfahren zur behandlung von viralen infectionen | |
| WO1992020352A1 (fr) | Substance destinee au traitement des maladies causees par des micro-organismes et procede d'elaboration et d'utilisation d'une telle substance | |
| US4499084A (en) | Ara-A Antiviral composition and method of administering the same | |
| RU2108797C1 (ru) | Способ получения антивирусного препарата на основе днк | |
| EP0978289A1 (fr) | Virucide contenant de l'iode | |
| DE69117923T2 (de) | Pharmazeutische zusammensetzungen zur aids-behandlung | |
| RU2232501C2 (ru) | Способ повышения естественной резистентности животных | |
| EP0561145A1 (fr) | Utilisation d'une matrice faite à base de chlorite pour la manufacture de préparations médicinales pour le traitement d'infections causées par le HIV | |
| RU2192870C1 (ru) | Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией | |
| RU2256460C2 (ru) | Способ лечения неспецифической бронхопневмонии у телят | |
| RU2058791C1 (ru) | Стимулятор репродуктивной способности у теплокровных животных | |
| RU2010565C1 (ru) | Препарат для лечения и профилактики острых желудочно-кишечных болезней новорожденных телят и способы профилактики и лечения | |
| CA1257203A (fr) | Dialyse avec du monophosphoryl lipide a | |
| RU2395278C1 (ru) | Способ получения комплексного препарата для профилактики и лечения патологий обмена веществ и нарушений функций иммунной системы животных | |
| RU2119334C1 (ru) | Антгельминтное средство | |
| RU2071774C1 (ru) | Способ лечения больных хроническими неспецифическими заболеваниями легких | |
| RU2000785C1 (ru) | Способ лечени кандидоза слизистой оболочки полости рта | |
| RU2098102C1 (ru) | Лекарственное средство для лечения железодефицитных анемий у детей | |
| RU1805959C (ru) | Способ борьбы с гастроэнтеритом вирусной этиологии у свиней | |
| RU2200547C2 (ru) | Препарат для лечения гепатоза животных | |
| RU2220717C2 (ru) | Препарат для лечения парвовирусного энтерита собак и способ его применения | |
| RU1787437C (ru) | Средство дл профилактики и лечени рыб при аэромонозе | |
| Al-Khayat et al. | Chelation of Ambilhar with Calcium and Magnesium | |
| RU2102067C1 (ru) | Способ профилактики и лечения желудочно-кишечных заболеваний телят | |
| WO1984001505A1 (fr) | Opsonines dans une dialyse peritoneale |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA FI HU JP PL RO SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG |
|
| CFP | Corrected version of a pamphlet front page | ||
| COP | Corrected version of pamphlet |
Free format text: FORM PCT/ISA/210 (EXTRA SHEET), ADDED |
|
| CR1 | Correction of entry in section i | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |